心肌梗死后β受体阻滞剂中断还是继续治疗
ABYSS研究为法国49个中心的多中心、开放标签、随机、非劣效性试验,纳入有心肌梗死病史、左心室射血分数至少40%且正在长期服用β受体阻滞剂、近6个月无心血管事件的患者3698例,1:1随机分为中断组1846例与继续组1852例。主要终点为死亡、非致死性心肌梗死、非致死性卒中或心血管原因住院的复合终点,非劣效界值为两组差异双侧95%CI上限<3个百分点。中位随访3.0年,中断组主要终点事件发生率23.8%(432/1812)vs 继续组21.1%(384/1821),风险差2.8个百分点(95%CI <0.1至5.5),风险比1.16(95%CI 1.01–1.33),非劣效性检验P=0.44,未达到非劣效。中断β受体阻滞剂似乎未改善患者生活质量。
要点
- 心肌梗死后长期服用β受体阻滞剂、左心室射血分数至少40%且近6个月无心血管事件的患者,中断治疗未达到非劣效。
- 中位随访3.0年,中断组主要终点事件23.8%(432/1812)vs 继续组21.1%(384/1821),风险差2.8个百分点(95%CI <0.1至5.5)。
- 风险比1.16(95%CI 1.01–1.33),非劣效性检验P=0.44,未达到预设的非劣效界值(95%CI上限<3个百分点)。
- 中断β受体阻滞剂似乎未改善以欧洲五维健康量表(EQ-5D)评估的生活质量。
- 该试验在法国49个中心进行,随机化距末次心肌梗死中位时间2.9年(四分位距1.2至6.4)。
适用人群与场景
- 有心肌梗死病史、正在接受长期β受体阻滞剂治疗、左心室射血分数至少40%、且近6个月无心血管事件的患者。
- 法国49个中心的多中心、开放标签、随机、非劣效性试验人群,共3698例随机分组(中断组1846例,继续组1852例)。
诊断标准与关键阈值
- 非劣效界值定义为两组差异双侧95%置信区间上限<3个百分点。
- 主要终点为死亡、非致死性心肌梗死、非致死性卒中或心血管原因住院的复合终点,取最长随访(至少1年)时的数据。
- 主要次要终点为欧洲五维健康量表(EQ-5D)生活质量问卷评分变化。
处置流程与药物剂量
- 中断组:中断长期β受体阻滞剂治疗;继续组:继续β受体阻滞剂治疗;随机化比例为1:1。
研究设计与关键结果
- 多中心、开放标签、随机、非劣效性试验,法国49个中心,3698例患者随机分为中断组1846例与继续组1852例。
- 随机化距末次心肌梗死中位时间2.9年(四分位距1.2至6.4),中位随访3.0年(四分位距2.0至4.0)。
- 主要终点事件:中断组432/1812例(23.8%)vs 继续组384/1821例(21.1%),风险差2.8个百分点(95%CI <0.1至5.5),风险比1.16(95%CI 1.01至1.33),非劣效性检验P=0.44。
- 中断β受体阻滞剂似乎未改善患者生活质量(以欧洲五维健康量表EQ-5D评估)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机、非劣效性试验。
- 非劣效性未达到:风险差95%CI上限5.5个百分点超过预设界值3个百分点,非劣效性检验P=0.44。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于有心肌梗死病史、左心室射血分数至少40%且近6个月无心血管事件、正在长期服用β受体阻滞剂的患者,中断β受体阻滞剂未达到非劣效,不支持以中断治疗来减少副作用或改善生活质量。
指南或共识出处
- ABYSS试验(ClinicalTrials.gov注册号NCT03498066;EudraCT号2017-003903-23),由法国卫生部与ACTION研究组资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment to reduce side effects and improve quality of life in patients with a history of uncomplicated myocardial infarction.
METHODS: In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we randomly assigned patients with a history of myocardial infarction, in a 1:1 ratio, to interruption or continuation of beta-blocker treatment. All the patients had a left ventricular ejection fraction of at least 40% while receiving long-term beta-blocker treatment and had no history of a cardiovascular event in the previous 6 months. The primary end point was a composite of death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for cardiovascular reasons at the longest follow-up (minimum, 1 year), according to an analysis of noninferiority (defined as a between-group difference of <3 percentage points for the upper boundary of the two-sided 95% confidence interval). The main secondary end point was the change in quality of life as measured by the European Quality of Life-5 Dimensions questionnaire.
RESULTS: A total of 3698 patients underwent randomization: 1846 to the interruption group and 1852 to the continuation group. The median time between the last myocardial infarction and randomization was 2.9 years (interquartile range, 1.2 to 6.4), and the median follow-up was 3.0 years (interquartile range, 2.0 to 4.0). A primary-outcome event occurred in 432 of 1812 patients (23.8%) in the interruption group and in 384 of 1821 patients (21.1%) in the continuation group (risk difference, 2.8 percentage points; 95% confidence interval [CI], <0.1 to 5.5), for a hazard ratio of 1.16 (95% CI, 1.01 to 1.33; P = 0.44 for noninferiority). Beta-blocker interruption did not seem to improve the patients' quality of life.
CONCLUSIONS: In patients with a history of myocardial infarction, interruption of long-term beta-blocker treatment was not found to be noninferior to a strategy of beta-blocker continuation. (Funded by the French Ministry of Health and ACTION Study Group; ABYSS ClinicalTrials.gov number, NCT03498066; EudraCT number, 2017-003903-23.).
参考来源
- Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024. PMID: 39213187. doi:10.1056/NEJMoa2404204
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。